nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP2E1—type 2 diabetes mellitus	0.126	0.387	CbGaD
Ondansetron—CYP1A2—type 2 diabetes mellitus	0.12	0.369	CbGaD
Ondansetron—CYP3A4—type 2 diabetes mellitus	0.0794	0.244	CbGaD
Ondansetron—SLC47A1—Metformin—type 2 diabetes mellitus	0.0434	0.0996	CbGbCtD
Ondansetron—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.0374	0.0859	CbGbCtD
Ondansetron—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.0234	0.0538	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Nateglinide—type 2 diabetes mellitus	0.0179	0.0411	CbGbCtD
Ondansetron—CYP3A7—Nateglinide—type 2 diabetes mellitus	0.0179	0.0411	CbGbCtD
Ondansetron—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0164	0.0377	CbGbCtD
Ondansetron—CYP2C9—Glipizide—type 2 diabetes mellitus	0.015	0.0345	CbGbCtD
Ondansetron—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.014	0.032	CbGbCtD
Ondansetron—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0134	0.0308	CbGbCtD
Ondansetron—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.0122	0.0279	CbGbCtD
Ondansetron—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.0119	0.0272	CbGbCtD
Ondansetron—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.0119	0.0272	CbGbCtD
Ondansetron—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.011	0.0251	CbGbCtD
Ondansetron—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0109	0.0249	CbGbCtD
Ondansetron—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0107	0.0246	CbGbCtD
Ondansetron—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.0106	0.0243	CbGbCtD
Ondansetron—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.01	0.023	CbGbCtD
Ondansetron—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00968	0.0222	CbGbCtD
Ondansetron—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00957	0.022	CbGbCtD
Ondansetron—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00955	0.0219	CbGbCtD
Ondansetron—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00905	0.0208	CbGbCtD
Ondansetron—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.009	0.0207	CbGbCtD
Ondansetron—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00873	0.02	CbGbCtD
Ondansetron—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00862	0.0198	CbGbCtD
Ondansetron—CYP3A5—Losartan—type 2 diabetes mellitus	0.00829	0.019	CbGbCtD
Ondansetron—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00823	0.0189	CbGbCtD
Ondansetron—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00789	0.0181	CbGbCtD
Ondansetron—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00763	0.0175	CbGbCtD
Ondansetron—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0069	0.0158	CbGbCtD
Ondansetron—CYP1A2—Losartan—type 2 diabetes mellitus	0.00617	0.0142	CbGbCtD
Ondansetron—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00608	0.0139	CbGbCtD
Ondansetron—CYP2C9—Losartan—type 2 diabetes mellitus	0.00556	0.0128	CbGbCtD
Ondansetron—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00523	0.012	CbGbCtD
Ondansetron—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00501	0.0115	CbGbCtD
Ondansetron—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00501	0.0115	CbGbCtD
Ondansetron—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00474	0.0109	CbGbCtD
Ondansetron—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00353	0.00811	CbGbCtD
Ondansetron—CYP3A4—Losartan—type 2 diabetes mellitus	0.00323	0.00742	CbGbCtD
Ondansetron—Alosetron—CYP2E1—type 2 diabetes mellitus	0.00141	0.387	CrCbGaD
Ondansetron—Alosetron—CYP1A2—type 2 diabetes mellitus	0.00134	0.369	CrCbGaD
Ondansetron—HTR3A—nerve—type 2 diabetes mellitus	0.00118	0.0837	CbGeAlD
Ondansetron—SLC47A2—kidney—type 2 diabetes mellitus	0.00114	0.0805	CbGeAlD
Ondansetron—SLC47A2—cortex of kidney—type 2 diabetes mellitus	0.00111	0.0784	CbGeAlD
Ondansetron—OPRM1—nerve—type 2 diabetes mellitus	0.00108	0.0767	CbGeAlD
Ondansetron—HTR1B—artery—type 2 diabetes mellitus	0.000998	0.0708	CbGeAlD
Ondansetron—Alosetron—CYP3A4—type 2 diabetes mellitus	0.000885	0.244	CrCbGaD
Ondansetron—HTR3A—islet of Langerhans—type 2 diabetes mellitus	0.000572	0.0405	CbGeAlD
Ondansetron—CYP3A7-CYP3A51P—nephron tubule—type 2 diabetes mellitus	0.000554	0.0393	CbGeAlD
Ondansetron—CYP3A7-CYP3A51P—cortex of kidney—type 2 diabetes mellitus	0.000474	0.0336	CbGeAlD
Ondansetron—SLC47A1—nephron tubule—type 2 diabetes mellitus	0.000452	0.0321	CbGeAlD
Ondansetron—SLC47A1—kidney—type 2 diabetes mellitus	0.000398	0.0282	CbGeAlD
Ondansetron—SLC47A1—cortex of kidney—type 2 diabetes mellitus	0.000387	0.0274	CbGeAlD
Ondansetron—CYP3A7—liver—type 2 diabetes mellitus	0.000362	0.0256	CbGeAlD
Ondansetron—SLC47A1—adipose tissue—type 2 diabetes mellitus	0.000358	0.0254	CbGeAlD
Ondansetron—HTR1B—cardiovascular system—type 2 diabetes mellitus	0.000347	0.0246	CbGeAlD
Ondansetron—KCNH2—islet of Langerhans—type 2 diabetes mellitus	0.000345	0.0244	CbGeAlD
Ondansetron—CYP3A7-CYP3A51P—liver—type 2 diabetes mellitus	0.000308	0.0218	CbGeAlD
Ondansetron—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000285	0.0202	CbGeAlD
Ondansetron—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.00028	0.0199	CbGeAlD
Ondansetron—SLC47A1—liver—type 2 diabetes mellitus	0.000251	0.0178	CbGeAlD
Ondansetron—KCNH2—cardiovascular system—type 2 diabetes mellitus	0.000249	0.0177	CbGeAlD
Ondansetron—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000229	0.0162	CbGeAlD
Ondansetron—CYP2E1—nephron tubule—type 2 diabetes mellitus	0.000214	0.0152	CbGeAlD
Ondansetron—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000203	0.0144	CbGeAlD
Ondansetron—CYP3A5—kidney—type 2 diabetes mellitus	0.000201	0.0143	CbGeAlD
Ondansetron—CYP3A5—pancreas—type 2 diabetes mellitus	0.0002	0.0142	CbGeAlD
Ondansetron—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000196	0.0139	CbGeAlD
Ondansetron—CYP2E1—cardiovascular system—type 2 diabetes mellitus	0.000192	0.0136	CbGeAlD
Ondansetron—CYP2E1—kidney—type 2 diabetes mellitus	0.000188	0.0133	CbGeAlD
Ondansetron—CYP2E1—cortex of kidney—type 2 diabetes mellitus	0.000183	0.013	CbGeAlD
Ondansetron—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000182	0.0129	CbGeAlD
Ondansetron—CYP3A4—kidney—type 2 diabetes mellitus	0.000151	0.0107	CbGeAlD
Ondansetron—CYP2D6—kidney—type 2 diabetes mellitus	0.000149	0.0105	CbGeAlD
Ondansetron—CYP1A2—liver—type 2 diabetes mellitus	0.000132	0.00936	CbGeAlD
Ondansetron—CYP3A5—liver—type 2 diabetes mellitus	0.000127	0.00903	CbGeAlD
Ondansetron—CYP2C9—liver—type 2 diabetes mellitus	0.000125	0.00888	CbGeAlD
Ondansetron—CYP2E1—liver—type 2 diabetes mellitus	0.000119	0.00842	CbGeAlD
Ondansetron—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000116	0.000845	CcSEcCtD
Ondansetron—Erythema—Losartan—type 2 diabetes mellitus	0.000116	0.000845	CcSEcCtD
Ondansetron—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000116	0.000842	CcSEcCtD
Ondansetron—Headache—Glipizide—type 2 diabetes mellitus	0.000116	0.000841	CcSEcCtD
Ondansetron—Tremor—Irbesartan—type 2 diabetes mellitus	0.000116	0.000841	CcSEcCtD
Ondansetron—Palpitations—Metformin—type 2 diabetes mellitus	0.000116	0.00084	CcSEcCtD
Ondansetron—Shock—Valsartan—type 2 diabetes mellitus	0.000116	0.000839	CcSEcCtD
Ondansetron—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000115	0.000836	CcSEcCtD
Ondansetron—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000115	0.000836	CcSEcCtD
Ondansetron—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000115	0.000833	CcSEcCtD
Ondansetron—Ill-defined disorder—Irbesartan—type 2 diabetes mellitus	0.000115	0.000833	CcSEcCtD
Ondansetron—Flatulence—Losartan—type 2 diabetes mellitus	0.000115	0.000832	CcSEcCtD
Ondansetron—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000114	0.000828	CcSEcCtD
Ondansetron—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000114	0.000828	CcSEcCtD
Ondansetron—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000114	0.000827	CcSEcCtD
Ondansetron—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000114	0.000826	CcSEcCtD
Ondansetron—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000114	0.000826	CcSEcCtD
Ondansetron—Agitation—Irbesartan—type 2 diabetes mellitus	0.000114	0.000825	CcSEcCtD
Ondansetron—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000114	0.000825	CcSEcCtD
Ondansetron—Urticaria—Glyburide—type 2 diabetes mellitus	0.000113	0.000821	CcSEcCtD
Ondansetron—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000113	0.00082	CcSEcCtD
Ondansetron—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000113	0.000818	CcSEcCtD
Ondansetron—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000113	0.000817	CcSEcCtD
Ondansetron—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000112	0.000811	CcSEcCtD
Ondansetron—Chest pain—Metformin—type 2 diabetes mellitus	0.000112	0.00081	CcSEcCtD
Ondansetron—Malaise—Irbesartan—type 2 diabetes mellitus	0.000112	0.000809	CcSEcCtD
Ondansetron—Headache—Pioglitazone—type 2 diabetes mellitus	0.000111	0.000806	CcSEcCtD
Ondansetron—Syncope—Irbesartan—type 2 diabetes mellitus	0.000111	0.000805	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000111	0.000804	CcSEcCtD
Ondansetron—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000111	0.000802	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00011	0.000801	CcSEcCtD
Ondansetron—Discomfort—Metformin—type 2 diabetes mellitus	0.00011	0.0008	CcSEcCtD
Ondansetron—Fatigue—Gliclazide—type 2 diabetes mellitus	0.00011	0.0008	CcSEcCtD
Ondansetron—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00011	0.000796	CcSEcCtD
Ondansetron—Hypotension—Valsartan—type 2 diabetes mellitus	0.00011	0.000796	CcSEcCtD
Ondansetron—Vision blurred—Losartan—type 2 diabetes mellitus	0.00011	0.000796	CcSEcCtD
Ondansetron—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000109	0.000794	CcSEcCtD
Ondansetron—Constipation—Gliclazide—type 2 diabetes mellitus	0.000109	0.000793	CcSEcCtD
Ondansetron—Pain—Gliclazide—type 2 diabetes mellitus	0.000109	0.000793	CcSEcCtD
Ondansetron—Tremor—Losartan—type 2 diabetes mellitus	0.000109	0.000791	CcSEcCtD
Ondansetron—Rash—Glimepiride—type 2 diabetes mellitus	0.000109	0.00079	CcSEcCtD
Ondansetron—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000109	0.000789	CcSEcCtD
Ondansetron—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000109	0.000789	CcSEcCtD
Ondansetron—Rash—Sitagliptin—type 2 diabetes mellitus	0.000109	0.000787	CcSEcCtD
Ondansetron—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000108	0.000787	CcSEcCtD
Ondansetron—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000108	0.000787	CcSEcCtD
Ondansetron—Headache—Glimepiride—type 2 diabetes mellitus	0.000108	0.000785	CcSEcCtD
Ondansetron—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.000108	0.000784	CcSEcCtD
Ondansetron—Cough—Irbesartan—type 2 diabetes mellitus	0.000108	0.000783	CcSEcCtD
Ondansetron—Headache—Sitagliptin—type 2 diabetes mellitus	0.000108	0.000782	CcSEcCtD
Ondansetron—Agitation—Losartan—type 2 diabetes mellitus	0.000107	0.000776	CcSEcCtD
Ondansetron—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000107	0.000773	CcSEcCtD
Ondansetron—Flushing—Ramipril—type 2 diabetes mellitus	0.000106	0.000772	CcSEcCtD
Ondansetron—Angioedema—Losartan—type 2 diabetes mellitus	0.000106	0.000772	CcSEcCtD
Ondansetron—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000105	0.000765	CcSEcCtD
Ondansetron—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000105	0.000764	CcSEcCtD
Ondansetron—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000105	0.000764	CcSEcCtD
Ondansetron—Shock—Metformin—type 2 diabetes mellitus	0.000105	0.000764	CcSEcCtD
Ondansetron—Malaise—Losartan—type 2 diabetes mellitus	0.000105	0.000762	CcSEcCtD
Ondansetron—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000105	0.000761	CcSEcCtD
Ondansetron—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000105	0.000761	CcSEcCtD
Ondansetron—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000105	0.000761	CcSEcCtD
Ondansetron—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000105	0.00076	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000105	0.000759	CcSEcCtD
Ondansetron—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000105	0.000759	CcSEcCtD
Ondansetron—Somnolence—Valsartan—type 2 diabetes mellitus	0.000104	0.000758	CcSEcCtD
Ondansetron—Syncope—Losartan—type 2 diabetes mellitus	0.000104	0.000757	CcSEcCtD
Ondansetron—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000104	0.000756	CcSEcCtD
Ondansetron—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000104	0.000755	CcSEcCtD
Ondansetron—Skin disorder—Metformin—type 2 diabetes mellitus	0.000104	0.000754	CcSEcCtD
Ondansetron—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000104	0.000751	CcSEcCtD
Ondansetron—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000103	0.00075	CcSEcCtD
Ondansetron—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000103	0.000747	CcSEcCtD
Ondansetron—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000103	0.000747	CcSEcCtD
Ondansetron—Palpitations—Losartan—type 2 diabetes mellitus	0.000103	0.000746	CcSEcCtD
Ondansetron—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000102	0.000743	CcSEcCtD
Ondansetron—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000102	0.000742	CcSEcCtD
Ondansetron—Asthenia—Glyburide—type 2 diabetes mellitus	0.000102	0.000741	CcSEcCtD
Ondansetron—Cough—Losartan—type 2 diabetes mellitus	0.000102	0.000737	CcSEcCtD
Ondansetron—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000102	0.000737	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000101	0.000736	CcSEcCtD
Ondansetron—Fatigue—Valsartan—type 2 diabetes mellitus	0.000101	0.000735	CcSEcCtD
Ondansetron—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000101	0.000733	CcSEcCtD
Ondansetron—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000101	0.000733	CcSEcCtD
Ondansetron—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000101	0.000732	CcSEcCtD
Ondansetron—Pruritus—Glyburide—type 2 diabetes mellitus	0.000101	0.000731	CcSEcCtD
Ondansetron—Constipation—Valsartan—type 2 diabetes mellitus	0.0001	0.000729	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.0001	0.000727	CcSEcCtD
Ondansetron—Fatigue—Orlistat—type 2 diabetes mellitus	0.0001	0.000726	CcSEcCtD
Ondansetron—Hypotension—Metformin—type 2 diabetes mellitus	0.0001	0.000725	CcSEcCtD
Ondansetron—Erythema—Ramipril—type 2 diabetes mellitus	9.98e-05	0.000724	CcSEcCtD
Ondansetron—Shock—Irbesartan—type 2 diabetes mellitus	9.93e-05	0.000721	CcSEcCtD
Ondansetron—Pain—Orlistat—type 2 diabetes mellitus	9.93e-05	0.00072	CcSEcCtD
Ondansetron—Chest pain—Losartan—type 2 diabetes mellitus	9.91e-05	0.000719	CcSEcCtD
Ondansetron—Vomiting—Bromocriptine—type 2 diabetes mellitus	9.9e-05	0.000719	CcSEcCtD
Ondansetron—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	9.9e-05	0.000718	CcSEcCtD
Ondansetron—Anxiety—Losartan—type 2 diabetes mellitus	9.88e-05	0.000717	CcSEcCtD
Ondansetron—Tachycardia—Irbesartan—type 2 diabetes mellitus	9.85e-05	0.000715	CcSEcCtD
Ondansetron—Rash—Bromocriptine—type 2 diabetes mellitus	9.82e-05	0.000713	CcSEcCtD
Ondansetron—Dermatitis—Bromocriptine—type 2 diabetes mellitus	9.81e-05	0.000712	CcSEcCtD
Ondansetron—Skin disorder—Irbesartan—type 2 diabetes mellitus	9.81e-05	0.000711	CcSEcCtD
Ondansetron—Discomfort—Losartan—type 2 diabetes mellitus	9.79e-05	0.00071	CcSEcCtD
Ondansetron—Headache—Bromocriptine—type 2 diabetes mellitus	9.76e-05	0.000708	CcSEcCtD
Ondansetron—Diarrhoea—Glyburide—type 2 diabetes mellitus	9.74e-05	0.000707	CcSEcCtD
Ondansetron—Dry mouth—Losartan—type 2 diabetes mellitus	9.69e-05	0.000703	CcSEcCtD
Ondansetron—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	9.61e-05	0.000697	CcSEcCtD
Ondansetron—Paraesthesia—Metformin—type 2 diabetes mellitus	9.61e-05	0.000697	CcSEcCtD
Ondansetron—Feeling abnormal—Orlistat—type 2 diabetes mellitus	9.57e-05	0.000694	CcSEcCtD
Ondansetron—CYP3A4—liver—type 2 diabetes mellitus	9.55e-05	0.00677	CbGeAlD
Ondansetron—Dyspnoea—Metformin—type 2 diabetes mellitus	9.54e-05	0.000692	CcSEcCtD
Ondansetron—Somnolence—Metformin—type 2 diabetes mellitus	9.51e-05	0.00069	CcSEcCtD
Ondansetron—Anaphylactic shock—Losartan—type 2 diabetes mellitus	9.5e-05	0.000689	CcSEcCtD
Ondansetron—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	9.49e-05	0.000689	CcSEcCtD
Ondansetron—Hypotension—Irbesartan—type 2 diabetes mellitus	9.43e-05	0.000684	CcSEcCtD
Ondansetron—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	9.42e-05	0.000683	CcSEcCtD
Ondansetron—CYP2D6—liver—type 2 diabetes mellitus	9.4e-05	0.00666	CbGeAlD
Ondansetron—Tremor—Ramipril—type 2 diabetes mellitus	9.35e-05	0.000679	CcSEcCtD
Ondansetron—Shock—Losartan—type 2 diabetes mellitus	9.35e-05	0.000678	CcSEcCtD
Ondansetron—Urticaria—Valsartan—type 2 diabetes mellitus	9.33e-05	0.000677	CcSEcCtD
Ondansetron—Nervous system disorder—Losartan—type 2 diabetes mellitus	9.32e-05	0.000676	CcSEcCtD
Ondansetron—Abdominal pain—Valsartan—type 2 diabetes mellitus	9.29e-05	0.000674	CcSEcCtD
Ondansetron—Tachycardia—Losartan—type 2 diabetes mellitus	9.27e-05	0.000673	CcSEcCtD
Ondansetron—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	9.26e-05	0.000672	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	9.24e-05	0.00067	CcSEcCtD
Ondansetron—Fatigue—Metformin—type 2 diabetes mellitus	9.22e-05	0.000669	CcSEcCtD
Ondansetron—Urticaria—Orlistat—type 2 diabetes mellitus	9.22e-05	0.000669	CcSEcCtD
Ondansetron—Abdominal pain—Orlistat—type 2 diabetes mellitus	9.18e-05	0.000666	CcSEcCtD
Ondansetron—Body temperature increased—Orlistat—type 2 diabetes mellitus	9.18e-05	0.000666	CcSEcCtD
Ondansetron—Asthenia—Gliclazide—type 2 diabetes mellitus	9.17e-05	0.000666	CcSEcCtD
Ondansetron—Agitation—Ramipril—type 2 diabetes mellitus	9.17e-05	0.000666	CcSEcCtD
Ondansetron—Constipation—Metformin—type 2 diabetes mellitus	9.15e-05	0.000664	CcSEcCtD
Ondansetron—Angioedema—Ramipril—type 2 diabetes mellitus	9.12e-05	0.000662	CcSEcCtD
Ondansetron—Paraesthesia—Irbesartan—type 2 diabetes mellitus	9.07e-05	0.000658	CcSEcCtD
Ondansetron—Vomiting—Glyburide—type 2 diabetes mellitus	9.05e-05	0.000657	CcSEcCtD
Ondansetron—Pruritus—Gliclazide—type 2 diabetes mellitus	9.05e-05	0.000656	CcSEcCtD
Ondansetron—Malaise—Ramipril—type 2 diabetes mellitus	9e-05	0.000653	CcSEcCtD
Ondansetron—Dyspnoea—Irbesartan—type 2 diabetes mellitus	9e-05	0.000653	CcSEcCtD
Ondansetron—Rash—Glyburide—type 2 diabetes mellitus	8.98e-05	0.000651	CcSEcCtD
Ondansetron—Somnolence—Irbesartan—type 2 diabetes mellitus	8.98e-05	0.000651	CcSEcCtD
Ondansetron—Dermatitis—Glyburide—type 2 diabetes mellitus	8.97e-05	0.000651	CcSEcCtD
Ondansetron—Syncope—Ramipril—type 2 diabetes mellitus	8.95e-05	0.000649	CcSEcCtD
Ondansetron—Headache—Glyburide—type 2 diabetes mellitus	8.92e-05	0.000647	CcSEcCtD
Ondansetron—Hypotension—Losartan—type 2 diabetes mellitus	8.88e-05	0.000644	CcSEcCtD
Ondansetron—Palpitations—Ramipril—type 2 diabetes mellitus	8.82e-05	0.00064	CcSEcCtD
Ondansetron—Feeling abnormal—Metformin—type 2 diabetes mellitus	8.82e-05	0.00064	CcSEcCtD
Ondansetron—Loss of consciousness—Ramipril—type 2 diabetes mellitus	8.77e-05	0.000637	CcSEcCtD
Ondansetron—Diarrhoea—Gliclazide—type 2 diabetes mellitus	8.75e-05	0.000635	CcSEcCtD
Ondansetron—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	8.75e-05	0.000635	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	8.72e-05	0.000632	CcSEcCtD
Ondansetron—Cough—Ramipril—type 2 diabetes mellitus	8.71e-05	0.000632	CcSEcCtD
Ondansetron—Fatigue—Irbesartan—type 2 diabetes mellitus	8.7e-05	0.000631	CcSEcCtD
Ondansetron—Hypersensitivity—Valsartan—type 2 diabetes mellitus	8.66e-05	0.000628	CcSEcCtD
Ondansetron—Convulsion—Ramipril—type 2 diabetes mellitus	8.65e-05	0.000627	CcSEcCtD
Ondansetron—Pain—Irbesartan—type 2 diabetes mellitus	8.63e-05	0.000626	CcSEcCtD
Ondansetron—Constipation—Irbesartan—type 2 diabetes mellitus	8.63e-05	0.000626	CcSEcCtD
Ondansetron—Hypersensitivity—Orlistat—type 2 diabetes mellitus	8.55e-05	0.00062	CcSEcCtD
Ondansetron—Paraesthesia—Losartan—type 2 diabetes mellitus	8.53e-05	0.000619	CcSEcCtD
Ondansetron—Urticaria—Metformin—type 2 diabetes mellitus	8.5e-05	0.000617	CcSEcCtD
Ondansetron—Chest pain—Ramipril—type 2 diabetes mellitus	8.5e-05	0.000617	CcSEcCtD
Ondansetron—Dyspnoea—Losartan—type 2 diabetes mellitus	8.47e-05	0.000615	CcSEcCtD
Ondansetron—Anxiety—Ramipril—type 2 diabetes mellitus	8.47e-05	0.000614	CcSEcCtD
Ondansetron—Abdominal pain—Metformin—type 2 diabetes mellitus	8.46e-05	0.000614	CcSEcCtD
Ondansetron—Dizziness—Gliclazide—type 2 diabetes mellitus	8.46e-05	0.000613	CcSEcCtD
Ondansetron—Somnolence—Losartan—type 2 diabetes mellitus	8.45e-05	0.000613	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	8.44e-05	0.000612	CcSEcCtD
Ondansetron—Asthenia—Valsartan—type 2 diabetes mellitus	8.43e-05	0.000611	CcSEcCtD
Ondansetron—Discomfort—Ramipril—type 2 diabetes mellitus	8.4e-05	0.000609	CcSEcCtD
Ondansetron—Asthenia—Orlistat—type 2 diabetes mellitus	8.33e-05	0.000604	CcSEcCtD
Ondansetron—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	8.32e-05	0.000604	CcSEcCtD
Ondansetron—Pruritus—Valsartan—type 2 diabetes mellitus	8.31e-05	0.000603	CcSEcCtD
Ondansetron—Dry mouth—Ramipril—type 2 diabetes mellitus	8.31e-05	0.000603	CcSEcCtD
Ondansetron—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	8.26e-05	0.000599	CcSEcCtD
Ondansetron—Pruritus—Orlistat—type 2 diabetes mellitus	8.21e-05	0.000596	CcSEcCtD
Ondansetron—Fatigue—Losartan—type 2 diabetes mellitus	8.19e-05	0.000594	CcSEcCtD
Ondansetron—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	8.15e-05	0.000591	CcSEcCtD
Ondansetron—Vomiting—Gliclazide—type 2 diabetes mellitus	8.13e-05	0.00059	CcSEcCtD
Ondansetron—Constipation—Losartan—type 2 diabetes mellitus	8.13e-05	0.000589	CcSEcCtD
Ondansetron—Pain—Losartan—type 2 diabetes mellitus	8.13e-05	0.000589	CcSEcCtD
Ondansetron—Rash—Gliclazide—type 2 diabetes mellitus	8.06e-05	0.000585	CcSEcCtD
Ondansetron—Dermatitis—Gliclazide—type 2 diabetes mellitus	8.06e-05	0.000584	CcSEcCtD
Ondansetron—Diarrhoea—Valsartan—type 2 diabetes mellitus	8.04e-05	0.000583	CcSEcCtD
Ondansetron—Urticaria—Irbesartan—type 2 diabetes mellitus	8.02e-05	0.000582	CcSEcCtD
Ondansetron—Shock—Ramipril—type 2 diabetes mellitus	8.02e-05	0.000581	CcSEcCtD
Ondansetron—Headache—Gliclazide—type 2 diabetes mellitus	8.01e-05	0.000581	CcSEcCtD
Ondansetron—Nervous system disorder—Ramipril—type 2 diabetes mellitus	7.99e-05	0.00058	CcSEcCtD
Ondansetron—Body temperature increased—Irbesartan—type 2 diabetes mellitus	7.98e-05	0.000579	CcSEcCtD
Ondansetron—Abdominal pain—Irbesartan—type 2 diabetes mellitus	7.98e-05	0.000579	CcSEcCtD
Ondansetron—Tachycardia—Ramipril—type 2 diabetes mellitus	7.95e-05	0.000577	CcSEcCtD
Ondansetron—Diarrhoea—Orlistat—type 2 diabetes mellitus	7.94e-05	0.000576	CcSEcCtD
Ondansetron—Skin disorder—Ramipril—type 2 diabetes mellitus	7.91e-05	0.000574	CcSEcCtD
Ondansetron—Feeling abnormal—Losartan—type 2 diabetes mellitus	7.83e-05	0.000568	CcSEcCtD
Ondansetron—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	7.77e-05	0.000564	CcSEcCtD
Ondansetron—Dizziness—Valsartan—type 2 diabetes mellitus	7.77e-05	0.000564	CcSEcCtD
Ondansetron—Dizziness—Orlistat—type 2 diabetes mellitus	7.68e-05	0.000557	CcSEcCtD
Ondansetron—Asthenia—Metformin—type 2 diabetes mellitus	7.68e-05	0.000557	CcSEcCtD
Ondansetron—Hypotension—Ramipril—type 2 diabetes mellitus	7.61e-05	0.000552	CcSEcCtD
Ondansetron—Pruritus—Metformin—type 2 diabetes mellitus	7.57e-05	0.000549	CcSEcCtD
Ondansetron—Urticaria—Losartan—type 2 diabetes mellitus	7.55e-05	0.000548	CcSEcCtD
Ondansetron—Abdominal pain—Losartan—type 2 diabetes mellitus	7.51e-05	0.000545	CcSEcCtD
Ondansetron—Body temperature increased—Losartan—type 2 diabetes mellitus	7.51e-05	0.000545	CcSEcCtD
Ondansetron—Vomiting—Valsartan—type 2 diabetes mellitus	7.47e-05	0.000542	CcSEcCtD
Ondansetron—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	7.44e-05	0.00054	CcSEcCtD
Ondansetron—Rash—Valsartan—type 2 diabetes mellitus	7.41e-05	0.000537	CcSEcCtD
Ondansetron—Dermatitis—Valsartan—type 2 diabetes mellitus	7.4e-05	0.000537	CcSEcCtD
Ondansetron—Vomiting—Orlistat—type 2 diabetes mellitus	7.38e-05	0.000535	CcSEcCtD
Ondansetron—Headache—Valsartan—type 2 diabetes mellitus	7.36e-05	0.000534	CcSEcCtD
Ondansetron—Diarrhoea—Metformin—type 2 diabetes mellitus	7.32e-05	0.000531	CcSEcCtD
Ondansetron—Rash—Orlistat—type 2 diabetes mellitus	7.32e-05	0.000531	CcSEcCtD
Ondansetron—Paraesthesia—Ramipril—type 2 diabetes mellitus	7.32e-05	0.000531	CcSEcCtD
Ondansetron—Dermatitis—Orlistat—type 2 diabetes mellitus	7.31e-05	0.000531	CcSEcCtD
Ondansetron—Headache—Orlistat—type 2 diabetes mellitus	7.27e-05	0.000528	CcSEcCtD
Ondansetron—Dyspnoea—Ramipril—type 2 diabetes mellitus	7.26e-05	0.000527	CcSEcCtD
Ondansetron—Asthenia—Irbesartan—type 2 diabetes mellitus	7.24e-05	0.000526	CcSEcCtD
Ondansetron—Somnolence—Ramipril—type 2 diabetes mellitus	7.24e-05	0.000525	CcSEcCtD
Ondansetron—Pruritus—Irbesartan—type 2 diabetes mellitus	7.14e-05	0.000518	CcSEcCtD
Ondansetron—Dizziness—Metformin—type 2 diabetes mellitus	7.07e-05	0.000513	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	7.03e-05	0.00051	CcSEcCtD
Ondansetron—Fatigue—Ramipril—type 2 diabetes mellitus	7.02e-05	0.00051	CcSEcCtD
Ondansetron—Hypersensitivity—Losartan—type 2 diabetes mellitus	7e-05	0.000508	CcSEcCtD
Ondansetron—Constipation—Ramipril—type 2 diabetes mellitus	6.97e-05	0.000505	CcSEcCtD
Ondansetron—Diarrhoea—Irbesartan—type 2 diabetes mellitus	6.91e-05	0.000501	CcSEcCtD
Ondansetron—Asthenia—Losartan—type 2 diabetes mellitus	6.82e-05	0.000495	CcSEcCtD
Ondansetron—Vomiting—Metformin—type 2 diabetes mellitus	6.8e-05	0.000493	CcSEcCtD
Ondansetron—Rash—Metformin—type 2 diabetes mellitus	6.75e-05	0.000489	CcSEcCtD
Ondansetron—Dermatitis—Metformin—type 2 diabetes mellitus	6.74e-05	0.000489	CcSEcCtD
Ondansetron—Pruritus—Losartan—type 2 diabetes mellitus	6.72e-05	0.000488	CcSEcCtD
Ondansetron—Feeling abnormal—Ramipril—type 2 diabetes mellitus	6.71e-05	0.000487	CcSEcCtD
Ondansetron—Headache—Metformin—type 2 diabetes mellitus	6.7e-05	0.000486	CcSEcCtD
Ondansetron—Dizziness—Irbesartan—type 2 diabetes mellitus	6.68e-05	0.000484	CcSEcCtD
Ondansetron—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	6.66e-05	0.000483	CcSEcCtD
Ondansetron—Diarrhoea—Losartan—type 2 diabetes mellitus	6.5e-05	0.000472	CcSEcCtD
Ondansetron—Urticaria—Ramipril—type 2 diabetes mellitus	6.47e-05	0.00047	CcSEcCtD
Ondansetron—Abdominal pain—Ramipril—type 2 diabetes mellitus	6.44e-05	0.000467	CcSEcCtD
Ondansetron—Body temperature increased—Ramipril—type 2 diabetes mellitus	6.44e-05	0.000467	CcSEcCtD
Ondansetron—Vomiting—Irbesartan—type 2 diabetes mellitus	6.42e-05	0.000466	CcSEcCtD
Ondansetron—Rash—Irbesartan—type 2 diabetes mellitus	6.37e-05	0.000462	CcSEcCtD
Ondansetron—Dermatitis—Irbesartan—type 2 diabetes mellitus	6.36e-05	0.000461	CcSEcCtD
Ondansetron—Headache—Irbesartan—type 2 diabetes mellitus	6.32e-05	0.000459	CcSEcCtD
Ondansetron—Dizziness—Losartan—type 2 diabetes mellitus	6.28e-05	0.000456	CcSEcCtD
Ondansetron—Vomiting—Losartan—type 2 diabetes mellitus	6.04e-05	0.000438	CcSEcCtD
Ondansetron—Hypersensitivity—Ramipril—type 2 diabetes mellitus	6e-05	0.000435	CcSEcCtD
Ondansetron—Rash—Losartan—type 2 diabetes mellitus	5.99e-05	0.000435	CcSEcCtD
Ondansetron—Dermatitis—Losartan—type 2 diabetes mellitus	5.99e-05	0.000434	CcSEcCtD
Ondansetron—Headache—Losartan—type 2 diabetes mellitus	5.95e-05	0.000432	CcSEcCtD
Ondansetron—Asthenia—Ramipril—type 2 diabetes mellitus	5.85e-05	0.000424	CcSEcCtD
Ondansetron—Pruritus—Ramipril—type 2 diabetes mellitus	5.76e-05	0.000418	CcSEcCtD
Ondansetron—Diarrhoea—Ramipril—type 2 diabetes mellitus	5.57e-05	0.000404	CcSEcCtD
Ondansetron—Dizziness—Ramipril—type 2 diabetes mellitus	5.39e-05	0.000391	CcSEcCtD
Ondansetron—Vomiting—Ramipril—type 2 diabetes mellitus	5.18e-05	0.000376	CcSEcCtD
Ondansetron—Rash—Ramipril—type 2 diabetes mellitus	5.14e-05	0.000373	CcSEcCtD
Ondansetron—Dermatitis—Ramipril—type 2 diabetes mellitus	5.13e-05	0.000372	CcSEcCtD
Ondansetron—Headache—Ramipril—type 2 diabetes mellitus	5.1e-05	0.00037	CcSEcCtD
Ondansetron—CYP3A5—Metabolism—GPX1—type 2 diabetes mellitus	3.37e-06	4.03e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—LEP—type 2 diabetes mellitus	3.36e-06	4.02e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APOE—type 2 diabetes mellitus	3.36e-06	4.02e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	3.33e-06	3.98e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—INS—type 2 diabetes mellitus	3.33e-06	3.98e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.32e-06	3.98e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	3.31e-06	3.96e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	3.31e-06	3.96e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	3.31e-06	3.96e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	3.31e-06	3.96e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.31e-06	3.96e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.31e-06	3.96e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	3.3e-06	3.95e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	3.29e-06	3.94e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CD36—type 2 diabetes mellitus	3.29e-06	3.94e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CD36—type 2 diabetes mellitus	3.28e-06	3.93e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	3.27e-06	3.92e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.27e-06	3.92e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	3.26e-06	3.91e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	3.26e-06	3.91e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPP2CA—type 2 diabetes mellitus	3.25e-06	3.89e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPP2CA—type 2 diabetes mellitus	3.24e-06	3.88e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	3.24e-06	3.87e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	3.24e-06	3.87e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.22e-06	3.85e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.22e-06	3.85e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.2e-06	3.83e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	3.18e-06	3.81e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	3.18e-06	3.8e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.17e-06	3.79e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	3.16e-06	3.78e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	3.14e-06	3.76e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ALB—type 2 diabetes mellitus	3.14e-06	3.75e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	3.13e-06	3.75e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	3.13e-06	3.75e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—MTHFR—type 2 diabetes mellitus	3.12e-06	3.73e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RELA—type 2 diabetes mellitus	3.11e-06	3.72e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—MTHFR—type 2 diabetes mellitus	3.11e-06	3.72e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	3.1e-06	3.71e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	3.1e-06	3.71e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	3.07e-06	3.67e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	3.06e-06	3.66e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	3.06e-06	3.66e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	3.06e-06	3.66e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARA—type 2 diabetes mellitus	3.06e-06	3.66e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.06e-06	3.66e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	3.05e-06	3.65e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	3e-06	3.59e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3R1—type 2 diabetes mellitus	3e-06	3.59e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—NOS3—type 2 diabetes mellitus	3e-06	3.59e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	3e-06	3.59e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	2.98e-06	3.56e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AGT—type 2 diabetes mellitus	2.96e-06	3.54e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	2.96e-06	3.54e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	2.95e-06	3.53e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	2.93e-06	3.51e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.92e-06	3.49e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.92e-06	3.49e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CALM1—type 2 diabetes mellitus	2.91e-06	3.49e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	2.91e-06	3.48e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	2.91e-06	3.48e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—APOE—type 2 diabetes mellitus	2.9e-06	3.47e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	2.9e-06	3.47e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—INS—type 2 diabetes mellitus	2.87e-06	3.44e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—APOA1—type 2 diabetes mellitus	2.87e-06	3.43e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	2.86e-06	3.43e-05	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.83e-06	3.39e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.83e-06	3.38e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.81e-06	3.36e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	2.8e-06	3.35e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.79e-06	3.34e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.78e-06	3.32e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.78e-06	3.32e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	2.77e-06	3.31e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.76e-06	3.31e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.76e-06	3.3e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.75e-06	3.29e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—type 2 diabetes mellitus	2.74e-06	3.29e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.7e-06	3.23e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.7e-06	3.23e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	2.7e-06	3.23e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.7e-06	3.23e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	2.7e-06	3.23e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	2.69e-06	3.21e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	2.68e-06	3.21e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.67e-06	3.2e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	2.67e-06	3.2e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	2.66e-06	3.19e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.65e-06	3.17e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	2.65e-06	3.17e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	2.65e-06	3.17e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	2.65e-06	3.17e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.65e-06	3.17e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.64e-06	3.16e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.63e-06	3.15e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.63e-06	3.15e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.63e-06	3.15e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	2.63e-06	3.14e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.62e-06	3.14e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.62e-06	3.13e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.57e-06	3.08e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	2.57e-06	3.08e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.57e-06	3.07e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	2.55e-06	3.05e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.54e-06	3.04e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PPARG—type 2 diabetes mellitus	2.53e-06	3.02e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	2.52e-06	3.02e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.52e-06	3.01e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.52e-06	3.01e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	2.5e-06	3e-05	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.5e-06	2.99e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	2.48e-06	2.97e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—INS—type 2 diabetes mellitus	2.48e-06	2.97e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.48e-06	2.96e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	2.47e-06	2.96e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.46e-06	2.95e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	2.46e-06	2.94e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SRC—type 2 diabetes mellitus	2.45e-06	2.93e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	2.44e-06	2.91e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	2.4e-06	2.88e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	2.4e-06	2.87e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	2.38e-06	2.85e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.38e-06	2.85e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	2.38e-06	2.84e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.37e-06	2.84e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.36e-06	2.83e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.36e-06	2.83e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.36e-06	2.83e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.34e-06	2.8e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	2.33e-06	2.79e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.32e-06	2.77e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.32e-06	2.77e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	2.31e-06	2.77e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	2.3e-06	2.76e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.3e-06	2.75e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	2.29e-06	2.74e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.29e-06	2.74e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	2.28e-06	2.73e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	2.28e-06	2.72e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ALB—type 2 diabetes mellitus	2.27e-06	2.72e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.27e-06	2.72e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	2.27e-06	2.71e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	2.25e-06	2.69e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	2.24e-06	2.69e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	2.21e-06	2.65e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	2.19e-06	2.62e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.19e-06	2.62e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	2.18e-06	2.61e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3R1—type 2 diabetes mellitus	2.17e-06	2.6e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—NOS3—type 2 diabetes mellitus	2.17e-06	2.6e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	2.17e-06	2.6e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	2.17e-06	2.6e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	2.17e-06	2.6e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	2.16e-06	2.58e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.16e-06	2.58e-05	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.16e-06	2.58e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	2.15e-06	2.57e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.14e-06	2.57e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.14e-06	2.56e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	2.13e-06	2.55e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	2.13e-06	2.55e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.12e-06	2.54e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	2.12e-06	2.54e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.1e-06	2.52e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	2.1e-06	2.52e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	2.08e-06	2.49e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	2.08e-06	2.49e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	2.07e-06	2.47e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	2.06e-06	2.46e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	2.05e-06	2.45e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	2.05e-06	2.45e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	2.05e-06	2.45e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	2.04e-06	2.44e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	2.04e-06	2.44e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	2.04e-06	2.44e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	2.03e-06	2.43e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.02e-06	2.42e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	2.02e-06	2.42e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2e-06	2.39e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—type 2 diabetes mellitus	1.99e-06	2.38e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	1.98e-06	2.37e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	1.98e-06	2.37e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.96e-06	2.35e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	1.95e-06	2.34e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.93e-06	2.31e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.89e-06	2.26e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	1.87e-06	2.24e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.86e-06	2.23e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	1.84e-06	2.2e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.81e-06	2.17e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.79e-06	2.15e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	1.78e-06	2.13e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	1.78e-06	2.13e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.76e-06	2.11e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.76e-06	2.11e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.76e-06	2.11e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.76e-06	2.1e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	1.75e-06	2.1e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	1.74e-06	2.09e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	1.74e-06	2.09e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.73e-06	2.07e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	1.72e-06	2.06e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.68e-06	2.01e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.67e-06	1.99e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	1.65e-06	1.97e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.64e-06	1.96e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.63e-06	1.95e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.61e-06	1.93e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.61e-06	1.92e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	1.6e-06	1.91e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.57e-06	1.88e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.57e-06	1.88e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.54e-06	1.85e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.54e-06	1.85e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	1.53e-06	1.83e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	1.53e-06	1.83e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.53e-06	1.83e-05	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.52e-06	1.82e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	1.52e-06	1.82e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.51e-06	1.8e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	1.49e-06	1.78e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.45e-06	1.74e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.45e-06	1.73e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.42e-06	1.7e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	1.41e-06	1.69e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	1.4e-06	1.67e-05	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	1.38e-06	1.65e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.37e-06	1.64e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	1.37e-06	1.64e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.35e-06	1.62e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.35e-06	1.61e-05	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.34e-06	1.61e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.33e-06	1.59e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	1.31e-06	1.56e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.31e-06	1.56e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.25e-06	1.5e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	1.2e-06	1.43e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.17e-06	1.4e-05	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.16e-06	1.39e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.15e-06	1.38e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.05e-06	1.26e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.01e-06	1.21e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.01e-06	1.21e-05	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—type 2 diabetes mellitus	9.99e-07	1.2e-05	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	9.97e-07	1.19e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	9.22e-07	1.1e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	7.09e-07	8.49e-06	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	7.03e-07	8.41e-06	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	6.01e-07	7.19e-06	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	4.64e-07	5.55e-06	CbGpPWpGaD
